(NEW YORK) -- The U.S. Food and Drug Administration Friday approved a new drug to treat advanced prostate cancer that isn't responding to other therapies, Health Day reports.
The drug, enzalutamide, which will be sold under the brand name Xtandi, interferes with production of testosterone, which encourages prostate tumors to grow. The FDA said it is intended for men who are experiencing a recurrence or spread of prostate cancer in spite of hormone therapy or chemotherapy. The drug was approved under the agency's priority review program for drugs that may be capable of significantly advancing current treatment, according to Health Day.
Xtandi will be marketed by Astellas Pharma U.S. Inc. of Northbrook, Ill. and Medivation Inc. of San Francisco.
Copyright 2012 ABC News Radio